J&J and AbbVie are competing for the same Crohn’s disease market with their respective IL-23 drugs, Tremfya and Skyrizi. On Wednesday, J&J’s Janssen unit revealed data it thinks could prove a key…
Protein degradation is one of the hot drug classes of the future, but competitors are piling in with the likes of C4, Arvinas, Frontier Medicines and Vividion jostling for position. A new startup…
New follow-up data suggest that AstraZeneca’s long-acting antibody can protect high-risk populations from contracting Covid-19 for as long as six months, beefing up the case for it as a form of…
A 178-acre property on a stretch of the Pittsburgh riverfront used to be the home of an old steel mill that shut down in the 1990s. Now, it will get an upgrade from a $100 million grant out of the…
Another week, another win for the North Carolina biotech community. This time, it’s Thermo Fisher Scientific, the Massachusetts-based contract giant, that recently announced it had plans to build a…
Hovione is going global with its manufacturing expansion, from New Jersey all the way to Portugal. The CDMO announced last week it would put $170 million into expansions in Portugal, Ireland and NJ, in an effort to increase its global capacity by 25%. The move follows an ongoing effort since 2016
Johnson & Johnson has a lofty goal to become a $60 billion-a-year drugmaker by 2025. To reach that goal, the healthcare giant is going to take a crack at a couple of viruses that have long eluded…
It’s not a buyout, but Gilead is doubling down on Arcus’ immuno-oncology programs as it decides to snap up work on three new targets.
Pfizer must have liked what it saw in data presented by Cardiff Oncology for a challenger in KRAS-mutated cancers. The Big Pharma is putting up a $15 million equity investment in the biotech to help…
Scientists at Children’s National Hospital identified peptides that are unique to medulloblastoma tumors and then engineered T cells so they could recognize and target those proteins. They believe the…
